This is an open label, randomized, controlled clinical trial. The primary aim of this project
is to determine the safety and tolerability of NF135.C10 sporozoite immunization under
chemoprophylaxis against homologous and heterologous challenge infection.
Phase:
N/A
Details
Lead Sponsor:
Radboud University
Collaborator:
The PATH Malaria Vaccine Initiative (MVI)
Treatments:
Atovaquone Atovaquone, proguanil drug combination Lumefantrine Mefloquine Proguanil Vaccines